GlassScriptPhysician profile
Neil Chesen
NPI 1801890843
$1,726.76
in general payments reported to CMS, 2019-2025
18 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $235 · 2021: $203 · 2022: $311 · 2023: $260 · 2024: $330 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824 · Debt Forgiveness: $38.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.31 |
| Debt Forgiveness | $38.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $369.17 | 2020-2025 | Tryptyr, Clareon, Simbrinza |
| Glaukos Corporation | $211.80 | 2020-2024 | Idose |
| Bausch & Lomb Americas INC. | $187.18 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $182.10 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $160.79 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $127.00 | 2019-2025 | |
| Abbvie INC. | $97.64 | 2022-2025 | Vuity, Lumigan |
| Allergan, INC. | $66.95 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.38 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $54.58 | 2019-2020 | |
| Oyster Point Pharma, INC. | $46.81 | 2023-2024 | Tyrvaya |
| Baxter Healthcare | $38.71 | 2023 | |
| Coopervision INC. | $37.46 | 2022-2023 | Myday Contact Lens |
| Shire North American Group INC | $20.06 | 2019 | |
| Aerie Pharmaceuticals, INC. | $19.98 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Amgen INC. | $16.33 | 2025 | Tepezza |
| Alcon Research LLC | $14.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Chesen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.